106 related articles for article (PubMed ID: 38824435)
1. Comparison of prophylaxis and preemptive strategy as cytomegalovirus prevention in liver transplant recipients.
Camus C; Poinot M; Pronier C; Rayar M; Neillon AL; Latournerie M; Lagathu G; Revest M
Transpl Infect Dis; 2024 Jun; 26(3):e14282. PubMed ID: 38824435
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
4. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
5. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
6. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
8. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
9. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients.
Torre-Cisneros J; Madueño JA; Herrero C; de la Mata M; Gonzalez R; Rivero A; Miño G; Sánchez-Guijo P
Clin Microbiol Infect; 2002 Dec; 8(12):773-80. PubMed ID: 12519350
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
[TBL] [Abstract][Full Text] [Related]
13. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
14. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
[TBL] [Abstract][Full Text] [Related]
15. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
16. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
17. Delayed-onset primary cytomegalovirus disease after liver transplantation.
Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
[TBL] [Abstract][Full Text] [Related]
18. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
